Side-by-side research comparison of IGF-1 and Ipamorelin across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 62 IGF-1 studies and 36 Ipamorelin studies.
| IGF-1 | Ipamorelin | |
|---|---|---|
| Drug class | growth factor | ghrh secretagogue, ghrelin mimetic |
| Studies in corpus | 62 | 36 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | cohort · 3 rct · 20 other · 15 case series · 1 case report · 1 preclinical animal · 9 review · 2 in vitro · 2 | other · 6 preclinical animal · 16 in vitro · 3 rct · 2 review · 1 |
| Studies with explicit sample size | 16 | 3 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real IGF-1 and Ipamorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 17 IGF-1 batches across 10 manufacturers, 99.17% avg purity.
We tested 2113 Ipamorelin batches across 690 manufacturers, 99.5% avg purity.
We hold deeper lab coverage on Ipamorelin (2113 batches tested). Ipamorelin edges ahead on average measured purity (99.17% vs 99.5%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on IGF-1 or Ipamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.